Monday, December 06, 2021

NEWS

Caricom expresses interest in Cuban-made Covid-19 vaccines

Caricom expresses interest in Cuban-made Covid-19 vaccines

Georgetown, Mar 31 (Prensa Latina) The Caribbean Community (Caricom) on Wednesday expressed interest in the vaccine candidates developed by Cuba to fight Covid-19.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

According to the Caricom Today website, member countries are exploring the possibility of obtaining Cuba’s Soberana 02 vaccine, a candidate that is expected to be the first to be approved for general administration.

The article, written by Elizabeth Morgan, a specialist in International Trade Policy, pointed out that Cuba is the only country in Latin America and the Caribbean that is developing Covid-19 vaccines, and nations such as Jamaica and Suriname have already shown interest in receiving these vaccines whenever possible.

Morgan pointed out that this is ‘a truly praiseworthy achievement by Cuba’, a small state that has four vaccine candidates in different stages of development recognized by the World Health Organization (WHO).

She explained that Soberana 02 is one of the two vaccines created at the Finlay Vaccines Institute, while the other ones were created by the Genetic Engineering and Biotechnology Center (CIGB).

The expert emphasized that there is long-standing cooperation between the regional bloc and Cuba, in addition to a Caricom-Cuba trade agreement.

She stressed that since the triumph of the Revolution in 1959 and after the imposition of the United States trade blockade in 1962, Cuba has had to become self-sufficient to mitigate its effects.

jg/abo/mem/dla

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.